Different androgen deprivation therapies might have a differential impact on cognition - An analysis from a population-based study using time-dependent exposure model
- PMID: 31918180
- DOI: 10.1016/j.canep.2019.101657
Different androgen deprivation therapies might have a differential impact on cognition - An analysis from a population-based study using time-dependent exposure model
Abstract
Background: Androgen deprivation therapy (ADT) remains the mainstay treatment for locally advanced or metastatic prostate cancer (PC). However, potential effects of ADT treatment on neurocognitive dysfunction remain unclear. The present study was conducted to assess the relation between ADT treatment and risk of cognitive decline in Asian men with PC.
Methods: A population-based cohort of 24,464 men with PC, each newly diagnosed between 2000 and 2008, was selected from the Taiwan National Health Insurance Database. Subjects were further grouped by treatment as non-ADT (n = 4685) or ADT (n = 12,740), members of the latter subjected to bilateral orchiectomy or medical treatment (ie, luteinizing hormone-releasing hormone agonists, antiandrogens, or combination therapy). A multivariable Cox proportional hazard model with ADT as time-dependent covariate was used to generate adjusted hazard ratios (HRs) of subsequent cognitive decline, including dementia, Alzheimer's disease (AD), and Parkinson's disease (PD).
Results: ADT showed a significant association with overall risk of cognitive decline (HR = 1.51, 95 % CI: 1.31-1.74), especially for PD, dementia, and non-Alzheimer dementia (non-AZD). When stratified by various ADT regimens, antiandrogen-only recipients displayed significantly heightened risks of subsequent AD, non-AZD, and PD. However, combined androgen blockade also imposed an increased risk of PD. There was no apparent correlation between duration of ADT exposure and cognitive dysfunction.
Conclusions: Various ADT therapies may have disparate impacts on cognitive function. Prospective studies exploring pertinent clinical characteristics more fully are needed to confirm these findings.
Keywords: Alzheimer disease; Androgen deprivation therapy; Cognitive decline; Combined androgen blockade; Dementia; Prostate cancer; Time-dependent exposure model.
Copyright © 2019 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors have no competing interests to declare.
Similar articles
-
Androgen deprivation increases the risk of fracture in prostate cancer patients: a population-based study in Chinese patients.Osteoporos Int. 2015 Sep;26(9):2281-90. doi: 10.1007/s00198-015-3135-9. Epub 2015 May 20. Osteoporos Int. 2015. PMID: 25990353
-
Type of Androgen Deprivation Therapy and Risk of Dementia Among Patients With Prostate Cancer in Taiwan.JAMA Netw Open. 2020 Aug 3;3(8):e2015189. doi: 10.1001/jamanetworkopen.2020.15189. JAMA Netw Open. 2020. PMID: 32865575 Free PMC article.
-
No increased risk of dementia in patients receiving androgen deprivation therapy for prostate cancer: a 5-year follow-up study.Asian J Androl. 2017 Jul-Aug;19(4):414-417. doi: 10.4103/1008-682X.179528. Asian J Androl. 2017. PMID: 27232853 Free PMC article.
-
Degarelix versus luteinizing hormone-releasing hormone agonists for the treatment of prostate cancer.Expert Opin Pharmacother. 2017 Jun;18(8):825-832. doi: 10.1080/14656566.2017.1328056. Epub 2017 May 19. Expert Opin Pharmacother. 2017. PMID: 28480768 Free PMC article. Review.
-
Androgen deprivation therapy for prostate cancer and dementia risk: a systematic review and meta-analysis.Prostate Cancer Prostatic Dis. 2017 Sep;20(3):259-264. doi: 10.1038/pcan.2017.10. Epub 2017 Mar 28. Prostate Cancer Prostatic Dis. 2017. PMID: 28349979 Review.
Cited by
-
Psychosocial Factors Associated with Cognitive Function in Prostate Cancer Survivors on Hormonal Treatments: A Systematic Review.Neuropsychol Rev. 2024 Apr 20. doi: 10.1007/s11065-024-09639-1. Online ahead of print. Neuropsychol Rev. 2024. PMID: 38642173 Review.
-
Androgen Deprivation Therapy for Prostate Cancer: Focus on Cognitive Function and Mood.Medicina (Kaunas). 2023 Dec 30;60(1):77. doi: 10.3390/medicina60010077. Medicina (Kaunas). 2023. PMID: 38256338 Free PMC article. Review.
-
Androgen deprivation therapy for prostate cancer and neurocognitive disorders: a systematic review and meta-analysis.Prostate Cancer Prostatic Dis. 2024 Jan 2. doi: 10.1038/s41391-023-00785-w. Online ahead of print. Prostate Cancer Prostatic Dis. 2024. PMID: 38167924
-
A Systematic Review on the Potential Acceleration of Neurocognitive Aging in Older Cancer Survivors.Cancers (Basel). 2023 Feb 14;15(4):1215. doi: 10.3390/cancers15041215. Cancers (Basel). 2023. PMID: 36831557 Free PMC article. Review.
-
[Testosterone and Alzheimer's disease].Probl Endokrinol (Mosk). 2022 Jun 24;68(5):97-107. doi: 10.14341/probl13136. Probl Endokrinol (Mosk). 2022. PMID: 36337024 Free PMC article. Russian.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical